Biogen (BIIB)
(Delayed Data from NSDQ)
$211.17 USD
-16.27 (-7.15%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIIB 211.17 -16.27(-7.15%)
Will BIIB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
Other News for BIIB
NEW YORK MARKET CLOSE: Stocks fly, ending fraught week with a flourish
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
AbbVie exits Alzheimer’s program on lack of differentiation
European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval